Market cap
$58 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-103 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.2
-
Face value
--
-
Shares outstanding
39,261,700
7 Years Aggregate
CFO
$-321.36 Mln
EBITDA
$-350.46 Mln
Net Profit
$-413.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
| 48.1 | -16.1 | 18.4 | -36.2 | -47.3 | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
Company
|
2022
|
2021
|
2020
|
|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
| -78.6 | -84.9 | 116.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tcr2 Therapeutics Inc (TCRR)
|
1.5 | 58.1 | 0.0 | -163.1 | -- | -111.5 | -- | 0.2 |
| 282.9 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 53.1 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 | |
| 131.6 | 17,452.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 181.5 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 480.8 | 11,084.5 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 20.4 | |
| 467.3 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 612.1 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 546.0 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 444.9 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout Tcr2 Therapeutics Inc (TCRR)
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells)... targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read more
-
Pres, CEO & Director
Dr. Garry E. Menzel M.B.A., Ph.D.
-
Pres, CEO & Director
Dr. Garry E. Menzel M.B.A., Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tcr2 Therapeutics Inc (TCRR)
What is the current share price of Tcr2 Therapeutics Inc (TCRR) Today?
The share price of Tcr2 Therapeutics Inc (TCRR) is $1.48 (NASDAQ) as of 01-Jun-2023 09:30 EDT. Tcr2 Therapeutics Inc (TCRR) has given a return of -47.28% in the last 3 years.
What is the current PB & PE ratio of Tcr2 Therapeutics Inc (TCRR)?
Since, TTM earnings of Tcr2 Therapeutics Inc (TCRR) is negative, P/E ratio is not available.
The P/B ratio of Tcr2 Therapeutics Inc (TCRR) is 0.22 times as on 01-Jun-2023, a 95 discount to its peers’ median range of 4.17 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.26
|
0.28
|
|
2021
|
-1.77
|
0.63
|
|
2020
|
-12.90
|
3.66
|
|
2019
|
-6.30
|
1.87
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Tcr2 Therapeutics Inc (TCRR)?
The 52-week high and low of Tcr2 Therapeutics Inc (TCRR) are Rs -- and Rs -- as of 15-Jun-2026.
What is the market cap of Tcr2 Therapeutics Inc (TCRR)?
Tcr2 Therapeutics Inc (TCRR) has a market capitalisation of $ 58 Mln as on 01-Jun-2023. As per SEBI classification, it is a company.
Should I invest in Tcr2 Therapeutics Inc (TCRR)?
Before investing in Tcr2 Therapeutics Inc (TCRR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.